MOTS-c: The Mitochondrial-Derived Peptide Rewriting Metabolism Research

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a 16-amino-acid peptide whose coding sequence sits inside the mitochondrial 12S rRNA gene. It was first characterized in 2015 by the Cohen laboratory at USC, and its discovery was striking for one reason: until then, peptides regulating systemic metabolism were thought to be encoded almost exclusively by the nuclear genome. MOTS-c upended that assumption by demonstrating that mitochondria themselves can produce signaling molecules with effects reaching far beyond the organelle.

Structurally, MOTS-c is short, hydrophobic in parts, and conserved across mammals — features consistent with a peptide that has been under selective pressure for a meaningful biological role rather than being a translational accident.

The most thoroughly characterized pathway for MOTS-c centers on AMP-activated protein kinase (AMPK), the cell's master energy sensor. In skeletal muscle, MOTS-c administration in preclinical models increases AMPK phosphorylation, drives glucose uptake independent of insulin, and reroutes folate-methionine cycle metabolites in ways that favor energy production over storage.

Downstream, MOTS-c has been shown in mouse models to improve insulin sensitivity, reduce diet-induced obesity, attenuate age-related insulin resistance, and exert effects on bone, adipose, and immune tissue. Researchers have described MOTS-c as a candidate 'exercise mimetic' because endogenous MOTS-c levels rise in response to physical exercise, and exogenous administration in mice recapitulates several adaptations normally produced by training.

The landmark 2015 Cell Metabolism paper from Lee et al. demonstrated that MOTS-c targets skeletal muscle, enhances glucose disposal, and prevents the metabolic decline seen in high-fat-diet-fed and aged mice. A follow-up line of work from Reynolds and colleagues in 2021 reported that MOTS-c administration extends physical capacity in middle-aged and old mice, and that it translocates to the nucleus under metabolic stress to regulate adaptive nuclear gene expression — an unusual retrograde mitochondria-to-nucleus signal.

Human observational data has linked circulating MOTS-c levels to insulin resistance, obesity, type 2 diabetes status, and a specific m.1382A>C variant within the MOTS-c coding region that is associated with reduced risk of type 2 diabetes in certain Asian populations. Direct interventional trials in humans remain very limited; most claims about MOTS-c outside preclinical models should be read carefully.

MOTS-c is supplied lyophilized. Researchers commonly store stock vials at -20°C, dry and dark, and minimize freeze-thaw cycles to preserve peptide integrity. As with any short peptide, exposure to high heat and repeated agitation can promote aggregation and loss of activity.

MOTS-c is provided strictly for in vitro and preclinical research use. It has not been approved by the FDA or any other regulatory body for human therapeutic use.

MOTS-c sits at the intersection of three rapidly moving fields: mitochondrial biology, aging research, and metabolic disease. For researchers, it represents both a tool — a way to perturb AMPK signaling and metabolic adaptation — and a target, since several pharmaceutical groups are actively studying mitochondrial-derived peptides as a class. Its continued investigation is likely to clarify how cells communicate energy status across organelle boundaries and whether the principles uncovered translate from preclinical models to human physiology.